Daveen Chopra compensation by year
Edwards Lifesciences Summary Compensation Table · all 2 fiscal years held| Component | FY2024 | FY2025 |
|---|---|---|
| Salary | $627,346 | $671,042 |
| Bonus | $0 | $0 |
| Stock awards | $1,284,500 | $1,764,066 |
| Option awards | $1,198,733 | $1,375,784 |
| Non-equity incentive | $556,133 | $824,239 |
| Pension and deferred compensation | $0 | $0 |
| All other | $53,779 | $60,611 |
| Total | $3,720,491 | $4,695,742 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Edwards Lifesciences Corp DEF 14A filed March 26, 2026, accession 0001099800-26-000015, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 37,275 | $3,177,694 | — |
| PSU | 21,706 | $1,850,437 | — |
| RSU | 16,100 | $1,372,525 | — |
| RSU | 14,175 | $1,208,419 | — |
| RSU | 9,200 | $784,300 | — |
| RSU | 7,000 | $596,750 | — |
| RSU | 5,250 | $447,563 | — |
| RSU | 3,238 | $276,040 | — |
| RSU | 3,205 | $273,226 | — |
| RSU | 813 | $69,308 | — |
| Option | 6,600 | — | $105.93 |
| Option | 24,950 | — | $88.78 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Edwards Lifesciences Corp's FY2025 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 14 award rows shown.
Insider transactions since the last proxy
15 Form 4 lines since the FY2025 proxy (filed March 26, 2026)current to 2026-09-24 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-09-11 | Tax withholding | — | 398 | $86.77 | 43,926 |
| 2026-08-26 | Exercise or conversion | — | 31,800 | $72.68 | 76,124 |
| 2026-08-26 | Exercise or conversion derivative | — | 31,800 | $0.00 | 0 |
| 2026-08-26 | Sale | — | 1,154 | $91.76 | 74,970 |
| 2026-08-26 | Sale | — | 30,646 | $90.99 | 44,324 |
| 2026-05-22 | Sale | — | 1,500 | $84.60 | 44,324 |
| 2026-05-11 | Exercise or conversion derivative | — | 13,583 | $0.00 | 0 |
| 2026-05-11 | Exercise or conversion | — | 13,583 | $0.00 | 53,362 |
The 8 most recent of 15 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments Edwards Lifesciences discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Disability | — | $2,349,577 | — | $2,349,577 |
| Involuntary termination without cause | $299,833 | — | — | $299,833 |
| Change in control and involuntary termination | $1,400,000 | $4,421,152 | $156,865 | $7,978,017 |
| Death | — | $2,349,577 | — | $2,349,577 |
Per the Potential Payments Upon Termination or Change in Control table in Edwards Lifesciences Corp's FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Edwards Lifesciences’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Bernard Zovighian | Chief Executive Officer and Director | $17,454,255 |
| Scott Ullem | Corporate Vice President, Chief Financial Officer | $6,050,554 |
| Larry Wood | Former Corporate Vice President and Group President, Transcatheter Aortic Valve Replacement and Surgical Structural Heart | $4,854,339 |
| Daveen Chopra · this page | Corporate Vice President, Transcatheter Mitral and Tricuspid Therapies | $4,695,742 |
| Donald Bobo | Corporate Vice President, Strategy & Corporate Development | $4,223,365 |
| Annette Brüls | Corporate Vice President, EMEACLA | $3,732,107 |
The full Edwards Lifesciences compensation record
free company briefThis page is one person within Edwards Lifesciences's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Edwards Lifesciences's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Edwards Lifesciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat